In addition, Pfizer has subscribed to Gene Logic's ToxShield software for assessing and ranking drug candidates based on their potential toxicity in humans.
Gene Logic also provides microarray services to Pfizer -- a program launched in March -- to determine potentially toxic effects of novel compounds on tissues of interest.
Pfizer has been a subscriber to Gene Logic's ToxExpress database since February 2000. Its renewed subscription runs for three years.
The companies did not disclose the financial terms of the subscriptions.